BNET Industries
Last Fiscal Year Sales:$12.1M
- Public
- DE
Dow Jones Description
Provider of Drug Discovery & Diagnostic Research Services
Co-CEO & Chief Business Officer
Joseph F. DonahueNumber of Employees 70
Peer Companies
NAICS Code Research and Development in the Social Sciences and Humanities: 541720
News & Analysis
Filter by
lion bioscience ag - All News and Analysis
BioWisdom Acquires the Bioinformatics Business of LION bioscience AG
BioWisdom Limited, a world leader in the development and application of Intelligence Networks for the pharmaceutical industry, announced today that it has acquired the bioinformatics business of LION bioscience AG ("LION"), which is based around the SRS suite of data integration products. In accordance with an agreement announced today,...
Schering AG extends license. (Business in Brief).(Lion Bioscience AG)(Brief Article)
Lion Bioscience AG has inked a sixyear global licensing deal with Schering AG for Lion DiscoveryCenter, a state-of-the-art open platform that ... Lion Bioscience AG has inked a sixyear global licensing deal with Schering AG for Lion DiscoveryCenter, a state-of-the-art open platform that...
Cross-border investor relations: worth the investment? Companies weighing the value of approaching overseas investors could take a lesson from the approach of a German bioscience company. (International IR).(LION Bioscience AG's international investor str
Reading a recent Wall Street Journal article makes it clear that former General Electric Co. CEO Jack Welch's personal fortune is now primarily invested in tax-free municipal bonds. While the article points out that Welch has allocated a small chunk of his assets for riskier technology...
LION bioscience AG Licenses iDEA Software to Pfizer
Business/Technology Editors and Health/Medical Writers BIOWIRE2K A tool to support drug discovery acceleration and research cost reduction through early identification of successful drug candidates LION bioscience AG (Neuer Markt: LIO, WKN 504 350, Nasdaq: LEON) today announced that Pfizer has purchased a worldwide license for LION's...
Executive Briefing
Former PerkinElmer Instruments Head Forms Company Boston, MA 1/24/01-Robert J. Rosenthal, former head of the Instrument Division of Perkin Elmer and of Thermo Optek, has announced the formation of Magellan Discovery Technologies, LLC. The company plans to build a franchise of analytical instrument companies by acquiring "scalable, stable...
Buyout Brings Complementary Technology Together
Biotech: Germany-Based Firm to Acquire Local Biotech for $35 Million Analysts are applauding Germany-based Lion Bioscience AG's acquisition of a local biotech firm. San Diego-based Trega Biosciences Inc.'s technologies will add another dimension to Lion's specialty of mining data which researchers need to discover and develop drugs, analysts...
LION BIOSCIENCE AG and Paradigm Genetics Inc.(strategic alliance)(Brief Article)
LION BIOSCIENCE AG and Paradigm Genetics Inc. have formed a five-year strategic alliance to co-develop and co-market a new plant and fungal metabolic profiling database that can be used for target identification and validation. Lion has also formed a strategic alliance with Celera Genomics for developing...
- 1
Decision Makers
| Name (plus bio) | Position |
|---|---|
| Joseph F. Donahue | Co-CEO & Chief Business Officer |
| Thure Etzold | Co-CEO & CTO |
| Peter Willinger | CFO, Vice President, Global Finance, Operations & Director |
| Kevin Wandryk | Vice President, Business Development |
| Jim Monahan | Director, Communications |
| Tracy Coffey | Director, Communications |
| Simon Beaulah | Product Manager |
| Franz-werner Haas | Secretary |
Effective June 3, 2004, Joseph Donahue was appointed Chief Business Officer of our U.S. subsidiary, LION bioscience Inc. He also leads our North American operations as President of our subsidiary LION bioscience Inc. He joined us in May 2003 from Spotfire, where he most recently served as Vice President of Global Life Sciences and Chemicals Markets. Prior to joining Spotfire, Mr. Donahue was Vice President of North American Sales at MDL Information Systems. During a fifteen-year tenure at MDL, Mr. Donahue held numerous positions of increasing responsibility in sales and marketing. He received degrees in Chemistry and Computer Science from Villanova
| Organization | Position | Status |
|---|---|---|
| LION Bioscience AG | Co-CEO & Chief Business Officer | Current |
| LION Bioscience AG | Board of Directors | Current |
Dr. Thure Etzold joined our company in July 1998 and currently serves as Managing Director of our subsidiary LION bioscience Ltd. in Cambridge, U.K. He also serves as Senior Vice President Product Development Biology at LION. He is also a group leader in the research program at the EBI (European Bioinformatics Institute) in Hinxton, U.K. Prior to joining our company, he was a staff scientist at the EMBL (European Molecular Biology Laboratory) in Heidelberg, Germany. Dr. Etzold holds a PhD from the Max-Planck-Institut für Zuechtungsforschung in Cologne, Germany and joined the Ph.D. program at the EMBL in Heidelberg, Germany.
| Organization | Position | Status |
|---|---|---|
| LION Bioscience AG | Co-CEO & CTO | Current |
| LION Bioscience AG | Board of Directors | Current |
Peter Willinger joined our company in November 1998 as Director Controlling and has served as Vice President Global Finance & Operations since October 2001. After studying business economics at the Mannheim University where he received his BA, Mr. Willinger worked as a controller for Rudolf Wild GmbH & Co KG in Heidelberg for eight years before he joined our company.
| Organization | Position | Status |
|---|---|---|
| LION Bioscience AG | CFO, Vice President, Global Finance, Operations & Director | Current |
| Organization | Position | Status |
|---|---|---|
| LION Bioscience AG | Vice President, Business Development | Current |
| Organization | Position | Status |
|---|---|---|
| LION Bioscience AG | Director, Communications | Current |
| LION Bioscience AG | Director, Communications | Former |
| Organization | Position | Status |
|---|---|---|
| LION Bioscience AG | Director, Communications | Current |
| LION Bioscience AG | Director, Communications | Former |
| Organization | Position | Status |
|---|---|---|
| LION Bioscience AG | Product Manager | Current |
Dr. Franz-Werner Haas serves as General Corporate Counsel and Head of Patent-department. Before he joined our company’s legal department in July 2002, Dr. Haas was assistant to the executive board of an international commercial and service enterprise. Key responsibilities of his activity were issues under corporate law, the coordination of national and international associated companies as well as the worldwide sales and distribution of goods. Dr. Haas holds a Doctor of Laws from the university of Saarbruecken, from the Katholike Universiteit Leuven/Belgium and a Master of Laws (LL.M.) from the University of Edinburgh/UK.
| Organization | Position | Status |
|---|---|---|
| LION Bioscience AG | Secretary | Current |
Industry Transcripts by Seeking Alpha
-
51jobs Q3 2009 Earnings Call Transcript
on Nov 23, 2009about JOBS
-
NetEase Q3 2009 Earnings Call Transcript
on Nov 18, 2009about NTES
-
Franklin Covey Co. F4Q09 (Qtr End 08/31/09) Earnings Call Transcript
on Nov 16, 2009about FC
-
Cellcom Israel Ltd. Q3 2009 Earnings Call Transcript
on Nov 16, 2009about CEL
-
URS Corporation Q3 2009 Earnings Call Transcript
on Nov 13, 2009about URS

